Middle Market Business Leaders Cautiously Optimistic Despite Continued Uncertainty

New data from Citizens captures how middle market companies are responding to economic and policy headwinds…

Flux Power to Host Fiscal First and Second Quarter 2025 Results Conference Call on Thursday, March 20, 2025 at 4:30 p.m. Eastern Time

VISTA, Calif.–(BUSINESS WIRE)–Flux Power Holdings, Inc. (NASDAQ: FLUX), a developer of advanced lithium-ion energy storage solutions…

Redpoint Global Named a Leader in Omdia Universe CDP Report

Analyst Group Cites Segmentation, Orchestration, and Data Quality as Key Strengths WELLESLEY, Mass.–(BUSINESS WIRE)–#CDP–Redpoint Global was…

NUBURU Takes Strategic Leap Forward: First Acquisition Step in Defense and Security Sector Completed

Initial 20% Acquisition Completed, Creating New Foundation to Deploy Laser Technology Applications CENTENNIAL, Colo.–(BUSINESS WIRE)–NUBURU, Inc.…

Mobile Infrastructure to Present at Sidoti Small Cap Virtual Conference on March 19

CINCINNATI–(BUSINESS WIRE)–Mobile Infrastructure Corporation (NYSE American: BEEP), owners of a diversified portfolio of parking assets throughout…

More Than Fitness: F45 Training Unveils “FIT” – a Unifying Parent Company Paving the Way for Holistic Wellness

By unifying the Company’s three key brands – F45 Training, FS8, and VAURA Pilates – FIT…

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent’s Orion® artificial…

BrightSpire Capital, Inc. Announces 2025 Annual Meeting of Stockholders

NEW YORK–(BUSINESS WIRE)–BrightSpire Capital, Inc. (NYSE: BRSP) (“BrightSpire Capital” or the “Company”) today announced the Board…

CSG Systems International to Hold First Quarter 2025 Earnings Conference Call on May 7

DENVER–(BUSINESS WIRE)–CSG® (NASDAQ: CSGS) invites you to participate in a conference call on Wednesday, May 7,…

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

– Long-Term Outcomes Reinforce the High Efficacy of Biktarvy® in People with HIV and HBV Coinfection…